<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unipolar major depression: Administering transcranial magnetic stimulation (TMS)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unipolar major depression: Administering transcranial magnetic stimulation (TMS)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unipolar major depression: Administering transcranial magnetic stimulation (TMS)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Holtzheimer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4160862290"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Many patients with unipolar major depression do not respond to standard treatment with pharmacotherapy and psychotherapy [<a href="#rid1">1,2</a>] and are thus candidates for noninvasive neuromodulation procedures such as repetitive transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT) [<a href="#rid3">3-5</a>]. Although ECT is more efficacious than repetitive TMS [<a href="#rid6">6,7</a>], patients may prefer repetitive TMS because it is better tolerated and unlike ECT, TMS does not require general anesthesia and induction of seizures.</p><p>Modern TMS was developed in 1985 and the US Food and Drug Administration approved TMS for treatment-resistant depression in 2008 [<a href="#rid8">8</a>]. Other neuropsychiatric disorders that have been treated with TMS include bipolar disorder, depersonalization/derealization disorder, generalized anxiety disorder, obsessive-compulsive disorder, chronic pain, Parkinson disease, posttraumatic stress disorder, schizophrenia, smoking cessation, stroke rehabilitation, and tinnitus [<a href="#rid8">8-21</a>]. In addition, TMS has been studied as a diagnostic tool [<a href="#rid22">22</a>].</p><p>This topic reviews standard techniques for performing TMS to treat unipolar major depression in adults and briefly describes experimental techniques. The indications, efficacy, and safety of standard TMS for unipolar depression are discussed elsewhere. Other neuromodulation procedures, including ECT, magnetic seizure therapy, focal electrically administered seizure therapy, transcranial direct current stimulation, transcranial low voltage pulsed electromagnetic fields, cranial electrical stimulation, vagus nerve stimulation, deep brain stimulation, direct cortical stimulation, and ablative neurosurgery, are also discussed separately, as is choosing treatment for treatment-resistant depression:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16519.html" rel="external">"Unipolar depression in adults: Overview of neuromodulation procedures"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16518.html" rel="external">"Unipolar depression in adults: Treatment with surgical approaches"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p></p><p class="headingAnchor" id="H2136752143"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Repetitive transcranial magnetic stimulation (TMS) treats major depression and other illnesses by modulating activity in cortical regions and associated neural circuits [<a href="#rid23">23</a>]. The intervention uses a large alternating electrical current passed through a metal coil placed against the scalp to generate rapidly alternating magnetic fields, which pass through the skull nearly unimpeded and induce electric currents that depolarize neurons in a focal area of the surface cortex; some TMS devices may also stimulate deeper brain structures [<a href="#rid8">8,24-26</a>]. The magnetic field generated by repetitive TMS is comparable to that of a standard magnetic resonance imaging (MRI) device (approximately 1.5 to 3 Tesla); however, the TMS field is focal (beneath the coil), whereas the MRI field is large and fills the room housing the MRI device [<a href="#rid25">25,27</a>].</p><p>Commercially available TMS devices can administer different types of stimulation, including surface cortical stimulation, deep stimulation, and theta burst stimulation. The efficacy, safety, and adverse effects of these standard TMS protocols are discussed separately. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)"</a>.)</p><p>TMS is the subject of ongoing research to evaluate indications and optimize administration, including the amount of electricity to use and the length of time the electric current passes through the coil, as well as placement of the coil and the number of treatment sessions (see <a class="local">'Treatment parameters'</a> below and <a class="local">'Stimulation site'</a> below). Experimental techniques for administering TMS include an accelerated schedule (multiple sessions per day) as well as high dose stimulation and bilateral stimulation. (See <a class="local">'Experimental techniques'</a> below.)</p><p class="headingAnchor" id="H250011393"><span class="h1">PRETREATMENT ASSESSMENT</span><span class="headingEndMark"> — </span>Prior to prescribing repetitive transcranial magnetic stimulation (TMS), clinicians should evaluate patients to confirm the primary diagnosis of treatment-resistant depression and whether the intervention can be used safely [<a href="#rid20">20</a>]. The assessment includes a psychiatric history and mental status examination, with emphasis upon depressive symptoms (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 1</a>), length of the current depressive episode, types and number of failed treatments during the present episode, as well as the number, length, and treatment history of prior depressive episodes. Evaluations should also include the patient’s current use of alcohol and risk of withdrawal, as well as use of other substances that may provoke seizures, such as cocaine, inhalants, phencyclidine, and psychostimulants.</p><p>In addition, a general medical history and a screening physical examination is performed; more detailed physical examination should be pursued as guided by the history and review of systems [<a href="#rid20">20,28</a>]. Laboratory tests and neuroimaging studies are obtained as guided by the history and examination [<a href="#rid29">29-31</a>]. The general medical work-up should emphasize risk factors for seizures and preexisting neurologic disease, including history of seizures, loss of consciousness, or traumatic brain injury (<a class="graphic graphic_table graphicRef130014" href="/d/graphic/130014.html" rel="external">table 2</a>) [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Personal and family (parent, sibling, or child) history of seizures and epilepsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intracranial masses and brain disorder/trauma (eg, brain surgery, congenital brain malformation, increased intracranial pressure, stroke, traumatic brain injury, tumor, or vascular abnormalities in the brain).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrolyte disturbance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications that can lower seizure threshold (eg, antipsychotics, <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, stimulants, tricyclic antidepressants, and <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>) (<a class="graphic graphic_table graphicRef106961" href="/d/graphic/106961.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent (eg, in the past few days) dose reduction or discontinuation of benzodiazepines or other anticonvulsants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metal in the head or neck.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sleep deprivation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions that might affect seizure threshold (eg, caffeine overuse or alcohol withdrawal) (<a class="graphic graphic_table graphicRef61807" href="/d/graphic/61807.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults", section on 'Acute symptomatic seizures'</a>.)</p><p></p><p>Referral to neurology or internal medicine is warranted if there are questions about the risk of seizures or other adverse effects. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Safety and adverse effects'</a>.)</p><p>Additional information about the initial assessment of patients undergoing repetitive TMS is discussed separately in the context of assessing patients for a diagnosis of unipolar depression. (See  <a class="medical medical_review" href="/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis", section on 'Assessment'</a>.)</p><p>Some clinicians have questioned recommendations to physically examine candidates for repetitive TMS due to its relative safety [<a href="#rid32">32</a>]. Nevertheless, we recommend a screening physical examination to identify general medical disorders that may contribute to the depressive syndrome or complicate use of TMS [<a href="#rid28">28</a>]. This approach is consistent with treatment guidelines from the National Network of Depression Centers and American Psychiatric Association [<a href="#rid3">3,5,20</a>].</p><p class="headingAnchor" id="H4181521122"><span class="h1">TREATMENT TEAM</span><span class="headingEndMark"> — </span>A psychiatrist or other qualified clinician should prescribe and supervise treatment of major depression with repetitive transcranial magnetic stimulation (TMS), although individual treatments are often administered by a nurse, physician assistant, or medical assistant [<a href="#rid20">20,25,27,28,33,34</a>]. For most practice settings in which someone other than the psychiatrist is operating the TMS device, the psychiatrist is immediately available [<a href="#rid25">25</a>]. We recommend that all providers receive training through a formal university affiliated or industry independent certification course, or through peer-to-peer training, as well as industry sponsored training on the specific repetitive TMS device to be used. In addition, all personnel should be trained to recognize and initially manage generalized seizures. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Seizure'</a>.)</p><p class="headingAnchor" id="H4136956547"><span class="h1">SETTING</span><span class="headingEndMark"> — </span>Repetitive transcranial magnetic stimulation (TMS) is generally an outpatient procedure, with patients awake and seated in a reclining chair during treatment. Anesthesia is not used and patients can thus drive themselves to and from sessions, which typically last approximately 30 to 40 minutes [<a href="#rid35">35</a>]. The equipment used to administer TMS is displayed in the graphic (<a class="graphic graphic_picture graphicRef113218" href="/d/graphic/113218.html" rel="external">picture 1</a>).</p><p class="headingAnchor" id="H2224556876"><span class="h1">MONITORING DURING TREATMENT</span><span class="headingEndMark"> — </span>During a course of repetitive transcranial magnetic stimulation, patients are evaluated at each session for adverse effects [<a href="#rid20">20,25</a>]. In addition, depressive symptoms are monitored with a clinician-administered or patient self-report standardized instrument that is administered weekly or every two weeks. Suitable self-report scales include the Patient Health Questionnaire – Nine Item (PHQ-9) (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 5</a>) [<a href="#rid25">25</a>]. Additional information about measurement-based care, including the PHQ-9, is discussed separately. (See  <a class="medical medical_review" href="/d/html/14860.html" rel="external">"Using scales to monitor symptoms and treat depression (measurement based care)"</a>.)</p><p class="headingAnchor" id="H1525740263"><span class="h1">STANDARD TECHNIQUES</span><span class="headingEndMark"> — </span>The US Food and Drug Administration has approved repetitive transcranial magnetic stimulation (TMS) devices that can administer different types of stimulation; these standard types of stimulation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Surface cortical stimulation</p><p class="bulletIndent2"><span class="glyph">•</span>High frequency</p><p class="bulletIndent2"><span class="glyph">•</span>Low frequency</p><p class="bulletIndent1"><span class="glyph">●</span>Deep stimulation</p><p class="bulletIndent1"><span class="glyph">●</span>Theta burst stimulation</p><p></p><p class="headingAnchor" id="H2999530315"><span class="h2">Surface cortical TMS</span><span class="headingEndMark"> — </span>Repetitive TMS that stimulates the surface cortex is called surface cortical TMS or superficial TMS. Surface cortical TMS is the most widely used and studied form of TMS.</p><p>The efficacy of surface cortical TMS is discussed separately. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Surface cortical TMS'</a>.)</p><p class="headingAnchor" id="H1873189403"><span class="h3">Treatment parameters</span><span class="headingEndMark"> — </span>TMS can be delivered either as a single pulse (stimulus) or as a series of pulses called a train; stimulation with a train is called repetitive TMS [<a href="#rid25">25,27</a>]. The depth of stimulation is approximately 2 to 3 cm beneath the coil (shaped like a figure-of-eight), and most repetitive TMS devices depolarize cortical neurons in a circular area with a diameter of approximately 2 to 3 cm. Parameters of repetitive TMS include [<a href="#rid8">8,20,25,36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequency – Number of magnetic pulses per second (hertz).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High (fast) frequency refers to stimulation delivered at &gt;1 pulse per second (typically 10 to 20 pulses per second). High frequency TMS is administered over the left dorsolateral prefrontal cortex and enhances cortical activity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low (slow) frequency denotes stimulation delivered at ≤1 pulse per second. Low frequency TMS is administered over the right dorsolateral prefrontal cortex and inhibits cortical activity.</p><p></p><p class="bulletIndent1">Indications for low frequency TMS include high risk of seizures, and initial treatment with high frequency TMS that is poorly tolerated (eg, stimulation site pain) or is ineffective [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intensity – Expressed as a percentage of the resting motor threshold, which is established before the first TMS treatment by stimulating the motor cortex and determining the minimum amount of energy that is required to evoke a motor response in a specific muscle group (generally the contralateral small hand muscles such as abductor pollicis brevis). The motor response is assessed visually or with electromyography. Intensity is generally set at 100 to 120 percent of resting motor threshold.</p><p></p><p class="bulletIndent1">During a course of treatment, the resting motor threshold is reassessed if there are changes in the patient’s clinical status that may increase cortical excitability and lower seizure threshold, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjustment of concurrent pharmacotherapy</p><p class="bulletIndent2"><span class="glyph">•</span>Sleep deprivation</p><p class="bulletIndent2"><span class="glyph">•</span>Changes in substance use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Train duration (on time; eg, 4 seconds).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intertrain interval – Time between successive trains (off time, eg, 26 seconds).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Number of trains per session (eg, 75 trains).</p><p></p><p>Most studies report the number of pulses per session (eg, 3000), which is calculated from the frequency, train duration, and number of trains per session. The number of pulses given during a specific time period, such as a treatment session, day, week, or treatment course, can be conceptualized as the dose of TMS.</p><p class="headingAnchor" id="H1289079121"><span class="h3">Stimulation site</span><span class="headingEndMark"> — </span>Most clinical trials of repetitive TMS for unipolar major depression have stimulated a single cortical site [<a href="#rid23">23</a>]. Generally, the left dorsal lateral prefrontal cortex is targeted, and neuroimaging of depressed patients has found hypoactivity in the dorsal lateral prefrontal cortex [<a href="#rid37">37</a>]. However, some trials have stimulated the right dorsal lateral prefrontal cortex, and other trials have sequentially or simultaneously stimulated two cortical sites [<a href="#rid38">38</a>]. TMS of the dorsomedial prefrontal cortex has also been studied [<a href="#rid39">39</a>].</p><p>Several methods have been developed to position the magnetic coil for stimulating the left dorsal lateral prefrontal cortex [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Perhaps the most common technique, which is relatively inexpensive and easy to implement, is performed by first identifying the optimal spot on the scalp for evoking a motor evoked potential in the hand muscles, and then advancing the coil 5 cm anteriorly in a parasagittal plane along the skull surface (some authorities measure 5.5 to 7 cm) [<a href="#rid25">25,36,40</a>]. Although this approach has been widely studied, its utility is limited because patients have varying brain sizes and morphology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The preferred coil positioning technique, based upon multiple studies and expert consensus opinion, is another relatively inexpensive approach called the “Beam F3” location system [<a href="#rid20">20,41,42</a>]. This method uses three skull measurements based upon techniques used to place electroencephalography electrodes, and is more precise than using a set distance from the motor cortex because the Beam F3 method accounts for differences in skull size.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuronavigation guided by magnetic resonance imaging scans has been used in some research protocols to localize the prefrontal cortex [<a href="#rid26">26,43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another method for coil positioning uses a stereotactic frame with mechanical arms to hold the coil in place with respect to the head [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H2851665461"><span class="h3">Acute treatment</span><span class="headingEndMark"> — </span>For acute treatment of unipolar major depression, repetitive TMS is usually administered by stimulating the left dorsal lateral prefrontal cortex daily (Monday through Friday) over four to six weeks, using the following parameters [<a href="#rid4">4,23,25,26,45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>10 magnetic pulses per second (10 hertz)</p><p class="bulletIndent1"><span class="glyph">●</span>3000 pulses per session</p><p class="bulletIndent1"><span class="glyph">●</span>100 to 120 percent of motor threshold (ie, the magnetic field intensity relative to the patient’s resting motor threshold)</p><p></p><p>However, the stimulation parameters required to optimize efficacy are not known, and administration of TMS is thus not standardized. As an example, meta-analyses have found that low frequency (≤1 pulse per second) and high frequency (≥5 pulses per second) TMS are each more effective than sham treatment, and that the benefits of low frequency and high frequency repetitive TMS are comparable. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Compared with sham treatment (placebo)'</a>.)</p><p>The number of treatments necessary for patients with acute major depression is not clear. Some authorities suggest that a trial of repetitive TMS should last a minimum of three to four weeks before determining whether the treatment is beneficial [<a href="#rid36">36</a>]. In addition, it is reasonable to extend treatment to six weeks and beyond six weeks for an additional two to six weeks for patients who have achieved a partial response that has not plateaued and for patients with a prior history of late response (eg, after 10 weeks) to antidepressant medications [<a href="#rid25">25</a>]. Evidence supporting treatment beyond six weeks includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In an observational study, 73 patients with unipolar major depression who did not respond to daily repetitive TMS for four to six weeks were treated for an additional six weeks; response (improvement from baseline on the depression rating scale ≥ 50 percent) occurred in 26 percent [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another observational study enrolled 61 patients who did not initially respond satisfactorily to acute TMS and then administered additional acute TMS, such that patients received a total of up to 12 weeks of acute TMS; remission occurred in 31 percent [<a href="#rid47">47</a>].</p><p></p><p>Treatments can be spaced rather than administered on a daily basis [<a href="#rid48">48</a>]. In a randomized trial, repetitive TMS given three days per week for six weeks (18 sessions) was compared with repetitive TMS given five days per week for four weeks (20 sessions) in 77 patients with major depression; improvement and tolerability were similar [<a href="#rid49">49</a>].</p><p>Safety measures for repetitive TMS include use of hearing protection (eg, ear plugs) and keeping oxygen and anticonvulsant medications available for treatment of seizures; these procedures are consistent with TMS guidelines [<a href="#rid20">20,33,50</a>]. The risk of hearing loss and seizures is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Safety and adverse effects'</a>.)</p><p>Acute repetitive TMS can be used with or without concurrent medications [<a href="#rid25">25</a>]. Concomitant psychotropic (eg, antidepressants) and nonpsychotropic medications are generally safe to use during a course of repetitive TMS for major depression [<a href="#rid51">51,52</a>], and most clinicians continue currently prescribed antidepressant drugs [<a href="#rid8">8,25</a>]. The pharmacotherapy regimen should be stable (eg, for four weeks) prior to adding TMS, which enables the treatment team to determine that clinical changes are due to the new treatment. Some clinicians taper and discontinue proconvulsant medications (eg, <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, tricyclics, and <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>). However, given the potential benefit of maintaining even partially effective medications, continuing these medications is reasonable, provided that clinicians carefully monitor the motor threshold to ensure that stimulation intensity does not exceed the recommended safety range [<a href="#rid53">53</a>]. Intensity is discussed elsewhere in this topic. (See <a class="local">'Treatment parameters'</a> above.)</p><p>Although questions have been raised as to whether benzodiazepines reduce the antidepressant efficacy of TMS [<a href="#rid8">8</a>]. It is reasonable to prescribe these medications during a course of repetitive TMS. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Predictors of response'</a>.)</p><p>For patients who complete acute treatment with repetitive TMS and are not receiving maintenance TMS (see <a class="local">'Maintenance treatment'</a> below), we typically discontinue TMS without a taper. However, it is reasonable for clinicians to taper TMS over two to three weeks before stopping it [<a href="#rid25">25</a>]. As an example, during a three-week taper, clinicians can administer three sessions in week 1, two sessions in week 2, and one session in the final week.</p><p class="headingAnchor" id="H3539916064"><span class="h3">Maintenance treatment</span><span class="headingEndMark"> — </span>For patients with unipolar major depression who respond to acute repetitive TMS and are at risk for recurrence, it is reasonable to use TMS for maintenance treatment; TMS is usually given in conjunction with antidepressant medications but can be used as monotherapy [<a href="#rid25">25</a>]. Maintenance TMS typically uses the same stimulation parameters and neuronavigation that were used during acute treatment, unless side effects necessitate changes [<a href="#rid50">50,54-56</a>]. However, the frequency of sessions for maintenance TMS has not been standardized, and it is not known whether any specific schedule is superior to another [<a href="#rid4">4</a>].</p><p>The most common maintenance TMS schedule appears to be one in which the number of sessions is gradually tapered over several months [<a href="#rid54">54</a>], and many clinicians determine the schedule based upon patient response [<a href="#rid25">25</a>]. Examples of specific, reasonable maintenance schedules that have been studied include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 42 patients, daily treatments were reduced to three sessions in week 1 of maintenance treatment, two sessions in week 2, and one session in week 3 [<a href="#rid50">50</a>]. After one session per week for four weeks, the schedule was tapered further to two sessions per month for two months and then to one session per month. The frequency of sessions was intermittently increased or decreased depending upon the patient’s clinical status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective observational study enrolled 35 patients who initially responded to acute TMS, then relapsed, and subsequently responded to a second course of acute TMS [<a href="#rid55">55</a>]. The maintenance TMS schedule was such that every month, patients received five sessions administered over three days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an 11-month randomized trial that compared active with sham maintenance TMS in 17 patients, maintenance TMS was delivered by gradually tapering treatment over three months from daily sessions to one session every two weeks [<a href="#rid56">56</a>].</p><p></p><p>It is not known how long patients should receive maintenance TMS. Across different studies, the duration has ranged from approximately six months to six years [<a href="#rid50">50,54,55,57</a>]. Based upon indirect evidence from studies of maintenance pharmacotherapy, patients with unipolar major depression who are at risk for recurrence of major depressive episodes are candidates for maintenance TMS lasting at least one year to three years. (See  <a class="medical medical_review" href="/d/html/14674.html" rel="external">"Unipolar depression in adults: Continuation and maintenance treatment", section on 'Duration'</a>.)</p><p class="headingAnchor" id="H3057643606"><span class="h2">Deep TMS</span><span class="headingEndMark"> — </span>Deep TMS is administered by commercially available repetitive TMS devices that theoretically stimulate brain structures beneath the superficial prefrontal cortex using magnetic coils (H coils); these H coils can induce a magnetic field with a deeper and wider distribution than the standard (figure eight) coils used for surface cortical TMS [<a href="#rid58">58-60</a>]. The depth of stimulation beneath with H coils is approximately 4 cm; H coils also stimulate surface cortical structures. It is not clear that stimulation of deeper brain structures with the H coils results in clinically or physiologically meaningful effects. Deep TMS is used to treat multiple neuropsychiatric disorders, including unipolar major depression, as well as obsessive-compulsive disorder, chronic pain, Parkinson disease, and stroke rehabilitation [<a href="#rid9">9-11,17</a>].</p><p>In randomized trials that treated unipolar major depression with deep TMS, treatment was administered as follows [<a href="#rid20">20,60,61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequency – 18 hertz</p><p class="bulletIndent1"><span class="glyph">●</span>Intensity – 120 percent of resting motor threshold</p><p class="bulletIndent1"><span class="glyph">●</span>Train duration (on time) – 2 seconds</p><p class="bulletIndent1"><span class="glyph">●</span>Intertrain interval (off time) – 20 seconds</p><p class="bulletIndent1"><span class="glyph">●</span>Number of magnetic pulses – 1980 pulses/session</p><p class="bulletIndent1"><span class="glyph">●</span>Stimulation site – Left dorsal lateral prefrontal cortex or prefrontal cortex</p><p></p><p>General information about repetitive TMS treatment parameters is discussed elsewhere in the context of surface cortical TMS. (See <a class="local">'Treatment parameters'</a> above.)</p><p>One session of deep TMS requires 20 to 30 minutes of stimulation, comparable to that for conventional surface cortical TMS [<a href="#rid60">60,61</a>]. Sessions occur each weekday for four weeks. Thus, the total number of daily sessions for an acute course of treatment with deep TMS is 20, comparable to that for surface cortical repetitive TMS. (See <a class="local">'Acute treatment'</a> above.)</p><p>The efficacy of deep TMS for unipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Deep TMS'</a>.)</p><p class="headingAnchor" id="H2821609564"><span class="h2">Theta burst TMS</span><span class="headingEndMark"> — </span>Theta burst (or intermittent theta burst) repetitive TMS utilizes magnetic pulses that are intended to mimic endogenous theta rhythms; this approach has been studied for unipolar major depression and other neuropsychiatric conditions, including chronic pain, posttraumatic stress disorder, stroke rehabilitation, and tinnitus [<a href="#rid12">12-14,16,62</a>].</p><p>In randomized trials that treated unipolar major depression with theta burst TMS, treatment was administered as follows [<a href="#rid62">62,63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequency – 5 hertz (five bursts/second; each burst consists of three 50 hertz stimulations)</p><p class="bulletIndent1"><span class="glyph">●</span>Intensity – 120 percent of resting motor threshold</p><p class="bulletIndent1"><span class="glyph">●</span>Train duration (on time) – Two seconds</p><p class="bulletIndent1"><span class="glyph">●</span>Intertrain interval (off time) – Eight seconds</p><p class="bulletIndent1"><span class="glyph">●</span>Number of magnetic pulses – 600 pulses/session</p><p class="bulletIndent1"><span class="glyph">●</span>Stimulation site – Left dorsal lateral prefrontal cortex</p><p></p><p>General information about repetitive TMS treatment parameters is discussed elsewhere in the context of surface cortical TMS. (See <a class="local">'Treatment parameters'</a> above.)</p><p>One session of theta burst TMS typically requires 3 to 10 minutes of stimulation, which is less than the 30 to 40 minutes required for conventional surface cortical repetitive TMS [<a href="#rid64">64</a>]. Sessions occur each weekday for four to six weeks. Thus, the total number of daily sessions for an acute course of treatment with theta burst TMS is 20 to 30, comparable to that for surface cortical TMS. (See <a class="local">'Acute treatment'</a> above.)</p><p>Multiple studies suggest that theta burst stimulation decreases the amplitude of motor-evoked potentials and also exerts longer lasting effects upon motor cortex excitability than surface cortical repetitive TMS [<a href="#rid65">65,66</a>].</p><p>The efficacy of theta burst TMS for unipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)", section on 'Theta burst TMS'</a>.)</p><p class="headingAnchor" id="H863627873"><span class="h1">EXPERIMENTAL TECHNIQUES</span><span class="headingEndMark"> — </span>Investigators are studying variations in administering repetitive transcranial magnetic stimulation (TMS) to patients with major depression [<a href="#rid67">67</a>], including an accelerated schedule (multiple sessions per day), high dose stimulation, and bilateral stimulation, which are described in the subsections below.</p><p class="headingAnchor" id="H801036574"><span class="h2">Accelerated TMS</span><span class="headingEndMark"> — </span>To address the logistical constraint of repetitive TMS protocols that call for five sessions per week for four to six weeks, investigators have administered multiple (eg, two or three) sessions per day for less than four weeks [<a href="#rid68">68-73</a>]. Evidence supporting accelerated (intensive) TMS includes a three-week trial that enrolled 52 patients with treatment-resistant depression and randomly assigned them to surface cortical TMS delivered either twice/day or once/day (1600 pulses per session) [<a href="#rid74">74</a>]. The study found that the likelihood of remission was greater with twice daily TMS (odds ratio 1.5). In addition, adverse effects were comparable for the two groups.</p><p>Other randomized trials in patients with treatment-resistant depression suggest that the benefit of accelerated TMS protocols, given on fewer treatment days, may be comparable to once daily protocols that involve more treatment days:</p><p class="bulletIndent1"><span class="glyph">●</span>A four-week trial compared an accelerated schedule of surface cortical TMS with a once daily schedule in 115 patients [<a href="#rid75">75</a>]. The schedule for accelerated TMS included 18 treatment sessions administered on six treatment days as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Week 1 – Three sessions/day on three treatment days</p><p class="bulletIndent2"><span class="glyph">•</span>Week 2 – Three sessions/day on two treatment days</p><p class="bulletIndent2"><span class="glyph">•</span>Week 3 – Three sessions/day on one treatment day</p><p></p><p class="bulletIndent1">Once daily TMS consisted of 20 treatment sessions given each weekday, for a total of 20 treatment days. Each treatment group received a total of 63,000 magnetic pulses. Remission with accelerated TMS and once daily TMS was comparable (15 and 12 percent of patients). However, pain at the stimulation site occurred in more patients who received accelerated TMS than once daily TMS (19 versus 4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The same research group conducted a four-week randomized trial that compared an accelerated schedule of theta burst TMS with a once daily schedule of surface cortical TMS in 74 patients [<a href="#rid63">63</a>]. The schedule for accelerated TMS included 21 treatment sessions administered on seven treatment days as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Week 1 – Three sessions/day on three treatment days</p><p class="bulletIndent2"><span class="glyph">•</span>Week 2 – Three sessions/day on two treatment days</p><p class="bulletIndent2"><span class="glyph">•</span>Week 3 and 4 – Three sessions/day on one treatment day</p><p></p><p class="bulletIndent1">Once daily TMS consisted of 20 treatment sessions given each weekday, for a total of 20 treatment days. The total number of magnetic pulses over the course of treatment with the accelerated schedule of theta burst TMS was 12,600 and with once daily surface cortical TMS was 63,000. Remission with accelerated TMS and once daily TMS was comparable (8 and 13 percent of patients), as were adverse effects.</p><p></p><p>One prospective observational study examined accelerated, high dose, theta burst repetitive TMS in 22 patients with treatment-resistant major depression [<a href="#rid44">44</a>]. After the investigators administered 10 sessions/day, with 1800 pulses/session for five consecutive days, remission occurred in 19 patients (86 percent).</p><p class="headingAnchor" id="H629134125"><span class="h2">High dose TMS</span><span class="headingEndMark"> — </span>The dose of repetitive TMS is the number of pulses given during a particular time period, such as a treatment session, day, week, or treatment course [<a href="#rid8">8</a>] (see <a class="local">'Treatment parameters'</a> above). Delivering more pulses than usual over the same treatment time frame (eg, 6000 pulses per session rather than 3000 pulses) has been tested as a means of improving response.</p><p>Randomized trials suggest that the efficacy of high dose and standard dose surface cortical TMS are comparable:</p><p>A four-week trial randomly assigned patients with treatment-resistant depression (n = 300) to one of four treatment arms utilizing surface cortical repetitive TMS [<a href="#rid76">76</a>]. Patients and clinical raters were blind to treatment, but clinicians administering TMS were not blind:</p><p class="bulletIndent1"><span class="glyph">●</span>High frequency TMS over the left dorsolateral prefrontal cortex was administered at a high dose (5625 pulses/session) or a standard dose (2250 pulses/session). Response (reduction of baseline symptoms ≥50 percent) with high dose and standard dose was comparable (47 and 53 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low frequency TMS over the right dorsolateral prefrontal cortex was administered at a high dose (3600 pulses/session) or standard dose (1200 pulses/session). Response with high dose and standard dose was comparable (48 and 49 percent of patients).</p><p></p><p>One prospective observational study examined high dose, accelerated, theta burst repetitive TMS in 22 patients with treatment-resistant major depression [<a href="#rid44">44</a>]. After the investigators administered 1800 pulses/session during 10 sessions each day, for five consecutive days, remission occurred in 19 patients (86 percent).</p><p class="headingAnchor" id="H1756015618"><span class="h2">Bilateral TMS</span><span class="headingEndMark"> — </span>Investigators have combined high frequency, surface cortical stimulation of the left dorsolateral prefrontal cortex (conventional TMS) with low frequency, surface cortical stimulation of the right dorsolateral prefrontal cortex to test the hypothesis that stimulation of both sides may activate complementary mechanisms that enhance efficacy. Patients receive conventional TMS plus low frequency TMS during each session, either simultaneously or sequentially. Although randomized trials have demonstrated that bilateral repetitive TMS is efficacious for unipolar treatment-resistant depression, it is not clear if bilateral TMS provides any advantage over conventional TMS:</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple trials indicate that bilateral repetitive TMS is superior to sham TMS [<a href="#rid77">77-80</a>]. As an example, a meta-analysis of 10 trials in 533 depressed patients found that response (eg, improvement of baseline symptoms ≥50 percent) was nearly five times more likely with bilateral TMS than sham TMS (odds ratio 4.9, 95% CI 2.8-8.8) [<a href="#rid81">81</a>]. In addition, all-cause discontinuation of treatment was comparable in the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, the relative efficacy and acceptability of bilateral TMS and conventional TMS is not clear due to conflicting results across studies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some studies indicate bilateral TMS is no better than conventional TMS:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A meta-analysis of four randomized trials (sample size not reported) found that response and all-cause discontinuation of treatment were comparable with bilateral TMS and conventional TMS [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A meta-analysis of seven randomized trials (n &gt;500 patients) compared bilateral TMS with unilateral surface cortical TMS (either conventional TMS or low frequency stimulation of the right dorsolateral prefrontal cortex); efficacy and all-cause discontinuation of treatment were each comparable in the two groups [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other studies indicate that bilateral TMS is more efficacious than conventional TMS. As an example, a meta-analysis of four randomized trials compared bilateral TMS with conventional TMS in 196 patients with treatment-resistant depression [<a href="#rid81">81</a>]. Response was more likely to occur with bilateral TMS (odds ratio 2.49, 95% CI 1.003-6.16), and all-cause discontinuation of treatment was comparable in the two groups.</p><p></p><p class="headingAnchor" id="H3727161128"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for transcranial magnetic stimulation (TMS)</strong> – Patients with unipolar major depression who do not respond to standard treatment with pharmacotherapy and psychotherapy are candidates for noninvasive neuromodulation procedures, including repetitive TMS. (See  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – TMS modulates activity in cortical regions and associated neural circuits by passing an alternating current through a metal coil placed against the scalp to generate rapidly alternating magnetic fields, which pass through the skull and induce electric currents that depolarize neurons in a focal area of the surface cortex; some TMS devices may also stimulate deeper brain structures. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment assessment</strong> – Prior to prescribing TMS, clinicians should evaluate patients to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Confirm the primary diagnosis of treatment-resistant depression and whether the intervention can be used safely (<a class="graphic graphic_table graphicRef130014" href="/d/graphic/130014.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The assessment includes a psychiatric history and mental status examination, with emphasis upon depressive symptoms (<a class="graphic graphic_table graphicRef89994" href="/d/graphic/89994.html" rel="external">table 1</a>) and types and number of failed treatments during the present episode.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluations should also include the patient’s current use of alcohol and risk of withdrawal, as well as use of other substances that may provoke seizures. In addition, a general medical history and a screening physical examination is performed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The general medical work-up should emphasize risk factors for seizures and preexisting neurologic disease (<a class="graphic graphic_table graphicRef130014" href="/d/graphic/130014.html" rel="external">table 2</a>). (See <a class="local">'Pretreatment assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standard types of stimulation</strong> – The US Food and Drug Administration has approved TMS devices that can administer different types of stimulation, including surface cortical stimulation, deep stimulation, and theta burst stimulation. TMS that stimulates the surface cortex is called surface cortical TMS, and is the most widely used and studied form of TMS. Deep TMS devices theoretically stimulate brain structures beneath the superficial prefrontal cortex, as well as surface cortical structures. Theta burst TMS utilizes magnetic pulses that are intended to mimic endogenous theta rhythms. (See <a class="local">'Standard techniques'</a> above and <a class="local">'Surface cortical TMS'</a> above and <a class="local">'Deep TMS'</a> above and <a class="local">'Theta burst TMS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stimulation parameters</strong> – Repetitive TMS is delivered as a series of pulses called a train. Stimulation parameters include frequency, intensity, train duration, intertrain interval, and number of trains per session. (See <a class="local">'Treatment parameters'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stimulation site</strong> – TMS generally targets the left dorsal lateral prefrontal cortex. (See <a class="local">'Stimulation site'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute treatment schedule</strong> – For acute treatment of unipolar major depression, TMS is usually administered each weekday over four to six weeks. (See <a class="local">'Acute treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance TMS</strong> – Maintenance TMS typically uses the same stimulation parameters that were used during acute treatment unless side effects intervene. The frequency of maintenance TMS treatments has not been standardized. (See <a class="local">'Maintenance treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Experimental types of stimulation</strong> – Investigational techniques for administering TMS include an accelerated schedule (multiple treatment sessions per day) as well as high dose stimulation and bilateral stimulation. (See <a class="local">'Experimental techniques'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.</a></li><li><a class="nounderline abstract_t">Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 2011; 34:1.</a></li><li><a class="nounderline abstract_t">American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.</a></li><li><a class="nounderline abstract_t">Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Can J Psychiatry 2016; 61:561.</a></li><li class="breakAll">American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. https://psychiatryonline.org/guidelines (Accessed on November 05, 2020).</li><li><a class="nounderline abstract_t">Eranti S, Mogg A, Pluck G, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry 2007; 164:73.</a></li><li><a class="nounderline abstract_t">Fitzgerald PB. Repetitive transcranial magnetic stimulation is not as effective as electroconvulsive therapy for major depression. Evid Based Ment Health 2007; 10:78.</a></li><li><a class="nounderline abstract_t">George MS. Whither TMS: A One-Trick Pony or the Beginning of a Neuroscientific Revolution? Am J Psychiatry 2019; 176:904.</a></li><li><a class="nounderline abstract_t">Selingardi PML, de Lima Rodrigues AL, da Silva VA, et al. Long-term deep-TMS does not negatively affect cognitive functions in stroke and spinal cord injury patients with central neuropathic pain. BMC Neurol 2019; 19:319.</a></li><li><a class="nounderline abstract_t">Cohen OS, Rigbi A, Yahalom G, et al. Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study. J Clin Neurophysiol 2018; 35:159.</a></li><li><a class="nounderline abstract_t">Shimizu T, Hosomi K, Maruo T, et al. Efficacy of deep rTMS for neuropathic pain in the lower limb: a randomized, double-blind crossover trial of an H-coil and figure-8 coil. J Neurosurg 2017; 127:1172.</a></li><li><a class="nounderline abstract_t">Schwippel T, Schroeder PA, Fallgatter AJ, Plewnia C. Clinical review: The therapeutic use of theta-burst stimulation in mental disorders and tinnitus. Prog Neuropsychopharmacol Biol Psychiatry 2019; 92:285.</a></li><li><a class="nounderline abstract_t">Hensel L, Grefkes C, Tscherpel C, et al. Intermittent theta burst stimulation applied during early rehabilitation after stroke: study protocol for a randomised controlled trial. BMJ Open 2019; 9:e034088.</a></li><li><a class="nounderline abstract_t">Gaertner M, Kong JT, Scherrer KH, et al. Advancing Transcranial Magnetic Stimulation Methods for Complex Regional Pain Syndrome: An Open-Label Study of Paired Theta Burst and High-Frequency Stimulation. Neuromodulation 2018; 21:409.</a></li><li><a class="nounderline abstract_t">Carmi L, Alyagon U, Barnea-Ygael N, et al. Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients. Brain Stimul 2018; 11:158.</a></li><li><a class="nounderline abstract_t">Philip NS, Barredo J, Aiken E, et al. Theta-Burst Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder. Am J Psychiatry 2019; 176:939.</a></li><li><a class="nounderline abstract_t">Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry 2019; 176:931.</a></li><li><a class="nounderline abstract_t">Dinur-Klein L, Dannon P, Hadar A, et al. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry 2014; 76:742.</a></li><li><a class="nounderline abstract_t">Kozel FA, Motes MA, Didehbani N, et al. Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial. J Affect Disord 2018; 229:506.</a></li><li><a class="nounderline abstract_t">McClintock SM, Reti IM, Carpenter LL, et al. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. J Clin Psychiatry 2018; 79.</a></li><li><a class="nounderline abstract_t">Kozel FA. Clinical Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder, Generalized Anxiety Disorder, and Bipolar Disorder. Psychiatr Clin North Am 2018; 41:433.</a></li><li><a class="nounderline abstract_t">Benussi A, Di Lorenzo F, Dell'Era V, et al. Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia. Neurology 2017; 89:665.</a></li><li><a class="nounderline abstract_t">George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010; 67:507.</a></li><li><a class="nounderline abstract_t">Allan C, Kalu UG, Sexton CE, Ebmeier KP. Transcranial stimulation in depression. Br J Psychiatry 2012; 200:10.</a></li><li><a class="nounderline abstract_t">Perera T, George MS, Grammer G, et al. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul 2016; 9:336.</a></li><li><a class="nounderline abstract_t">Lefaucheur JP, André-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014; 125:2150.</a></li><li><a class="nounderline abstract_t">George MS, Post RM. Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am J Psychiatry 2011; 168:356.</a></li><li><a class="nounderline abstract_t">McClintock SM, Reti IM, Carpenter LL, et al. Dr McClintock and Colleagues Reply. J Clin Psychiatry 2018; 79.</a></li><li><a class="nounderline abstract_t">Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.</a></li><li class="breakAll">American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).</li><li class="breakAll">Freudenreich O, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry, Third Edition, Levenson JL (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.249.</li><li><a class="nounderline abstract_t">Tendler A, Gersner R. Consensus Recommendations for rTMS in Depression: Not Entirely Correct! J Clin Psychiatry 2018; 79.</a></li><li><a class="nounderline abstract_t">Rossi S, Hallett M, Rossini PM, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009; 120:2008.</a></li><li><a class="nounderline abstract_t">Feifel D, Dunner DL, Press DZ, Board of Directors and Clinical Standards Committee of the Clinical TMS Society. Roles and Qualifications of TMS Treatment Team Members. J Clin Psychiatry 2018; 79.</a></li><li><a class="nounderline abstract_t">Lisanby SH. Update on magnetic seizure therapy: a novel form of convulsive therapy. J ECT 2002; 18:182.</a></li><li><a class="nounderline abstract_t">Fitzgerald PB, Daskalakis ZJ. A practical guide to the use of repetitive transcranial magnetic stimulation in the treatment of depression. Brain Stimul 2012; 5:287.</a></li><li><a class="nounderline abstract_t">Baeken C, De Raedt R. Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression. Dialogues Clin Neurosci 2011; 13:139.</a></li><li><a class="nounderline abstract_t">Fitzgerald PB, Hoy KE, Herring SE, et al. A double blind randomized trial of unilateral left and bilateral prefrontal cortex transcranial magnetic stimulation in treatment resistant major depression. J Affect Disord 2012; 139:193.</a></li><li><a class="nounderline abstract_t">Bakker N, Shahab S, Giacobbe P, et al. rTMS of the dorsomedial prefrontal cortex for major depression: safety, tolerability, effectiveness, and outcome predictors for 10 Hz versus intermittent theta-burst stimulation. Brain Stimul 2015; 8:208.</a></li><li><a class="nounderline abstract_t">Padberg F, George MS. Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression. Exp Neurol 2009; 219:2.</a></li><li><a class="nounderline abstract_t">Beam W, Borckardt JJ, Reeves ST, George MS. An efficient and accurate new method for locating the F3 position for prefrontal TMS applications. Brain Stimul 2009; 2:50.</a></li><li><a class="nounderline abstract_t">Trapp NT, Bruss J, King Johnson M, et al. Reliability of targeting methods in TMS for depression: Beam F3 vs. 5.5 cm. Brain Stimul 2020; 13:578.</a></li><li><a class="nounderline abstract_t">Schönfeldt-Lecuona C, Lefaucheur JP, Cardenas-Morales L, et al. The value of neuronavigated rTMS for the treatment of depression. Neurophysiol Clin 2010; 40:37.</a></li><li><a class="nounderline abstract_t">Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. Am J Psychiatry 2020; 177:716.</a></li><li><a class="nounderline abstract_t">Downar J, Blumberger DM, Daskalakis ZJ. Repetitive transcranial magnetic stimulation: an emerging treatment for medication-resistant depression. CMAJ 2016; 188:1175.</a></li><li><a class="nounderline abstract_t">Avery DH, Isenberg KE, Sampson SM, et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry 2008; 69:441.</a></li><li><a class="nounderline abstract_t">McDonald WM, Durkalski V, Ball ER, et al. Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety 2011; 28:973.</a></li><li><a class="nounderline abstract_t">Turnier-Shea Y, Bruno R, Pridmore S. Daily and spaced treatment with transcranial magnetic stimulation in major depression: a pilot study. Aust N Z J Psychiatry 2006; 40:759.</a></li><li><a class="nounderline abstract_t">Galletly C, Gill S, Clarke P, et al. A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments? Psychol Med 2012; 42:981.</a></li><li><a class="nounderline abstract_t">Connolly KR, Helmer A, Cristancho MA, et al. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry 2012; 73:e567.</a></li><li><a class="nounderline abstract_t">Rumi DO, Gattaz WF, Rigonatti SP, et al. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry 2005; 57:162.</a></li><li><a class="nounderline abstract_t">Ray S, Nizamie SH, Akhtar S, et al. Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of left prefrontal cortex in depression: a randomized sham controlled study. J Affect Disord 2011; 128:153.</a></li><li><a class="nounderline abstract_t">Mufti MA, Holtzheimer PE 3rd, Epstein CM, et al. Bupropion decreases resting motor threshold: a case report. Brain Stimul 2010; 3:177.</a></li><li><a class="nounderline abstract_t">Richieri R, Guedj E, Michel P, et al. Maintenance transcranial magnetic stimulation reduces depression relapse: a propensity-adjusted analysis. J Affect Disord 2013; 151:129.</a></li><li><a class="nounderline abstract_t">Fitzgerald PB, Grace N, Hoy KE, et al. An open label trial of clustered maintenance rTMS for patients with refractory depression. Brain Stimul 2013; 6:292.</a></li><li><a class="nounderline abstract_t">Benadhira R, Thomas F, Bouaziz N, et al. A randomized, sham-controlled study of maintenance rTMS for treatment-resistant depression (TRD). Psychiatry Res 2017; 258:226.</a></li><li><a class="nounderline abstract_t">O'Reardon JP, Blumner KH, Peshek AD, et al. Long-term maintenance therapy for major depressive disorder with rTMS. J Clin Psychiatry 2005; 66:1524.</a></li><li><a class="nounderline abstract_t">Levkovitz Y, Roth Y, Harel EV, et al. A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation. Clin Neurophysiol 2007; 118:2730.</a></li><li><a class="nounderline abstract_t">Zangen A, Roth Y, Voller B, Hallett M. Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil. Clin Neurophysiol 2005; 116:775.</a></li><li><a class="nounderline abstract_t">Filipčić I, Šimunović Filipčić I, Milovac Ž, et al. Efficacy of repetitive transcranial magnetic stimulation using a figure-8-coil or an H1-Coil in treatment of major depressive disorder; A randomized clinical trial. J Psychiatr Res 2019; 114:113.</a></li><li><a class="nounderline abstract_t">Levkovitz Y, Isserles M, Padberg F, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry 2015; 14:64.</a></li><li><a class="nounderline abstract_t">Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet 2018; 391:1683.</a></li><li><a class="nounderline abstract_t">Fitzgerald PB, Chen L, Richardson K, et al. A pilot investigation of an intensive theta burst stimulation protocol for patients with treatment resistant depression. Brain Stimul 2020; 13:137.</a></li><li><a class="nounderline abstract_t">Carpenter LL, Philip NS. The Future Is Now? Rapid Advances by Brain Stimulation Innovation. Am J Psychiatry 2020; 177:654.</a></li><li><a class="nounderline abstract_t">Berlim MT, McGirr A, Rodrigues Dos Santos N, et al. Efficacy of theta burst stimulation (TBS) for major depression: An exploratory meta-analysis of randomized and sham-controlled trials. J Psychiatr Res 2017; 90:102.</a></li><li><a class="nounderline abstract_t">Vernet M, Bashir S, Yoo WK, et al. Insights on the neural basis of motor plasticity induced by theta burst stimulation from TMS-EEG. Eur J Neurosci 2013; 37:598.</a></li><li><a class="nounderline abstract_t">Rosa MA, Lisanby SH. Somatic treatments for mood disorders. Neuropsychopharmacology 2012; 37:102.</a></li><li><a class="nounderline abstract_t">Holtzheimer PE 3rd, McDonald WM, Mufti M, et al. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety 2010; 27:960.</a></li><li><a class="nounderline abstract_t">Schulze L, Feffer K, Lozano C, et al. Number of pulses or number of sessions? An open-label study of trajectories of improvement for once-vs. twice-daily dorsomedial prefrontal rTMS in major depression. Brain Stimul 2018; 11:327.</a></li><li><a class="nounderline abstract_t">Modirrousta M, Meek BP, Wikstrom SL. Efficacy of twice-daily vs once-daily sessions of repetitive transcranial magnetic stimulation in the treatment of major depressive disorder: a retrospective study. Neuropsychiatr Dis Treat 2018; 14:309.</a></li><li><a class="nounderline abstract_t">Desbeaumes Jodoin V, Miron JP, Lespérance P. Safety and Efficacy of Accelerated Repetitive Transcranial Magnetic Stimulation Protocol in Elderly Depressed Unipolar and Bipolar Patients. Am J Geriatr Psychiatry 2019; 27:548.</a></li><li><a class="nounderline abstract_t">Baeken C, Vanderhasselt MA, Remue J, et al. Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients. J Affect Disord 2013; 151:625.</a></li><li><a class="nounderline abstract_t">McGirr A, Van den Eynde F, Tovar-Perdomo S, et al. Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial. J Affect Disord 2015; 173:216.</a></li><li><a class="nounderline abstract_t">Theleritis C, Sakkas P, Paparrigopoulos T, et al. Two Versus One High-Frequency Repetitive Transcranial Magnetic Stimulation Session per Day for Treatment-Resistant Depression: A Randomized Sham-Controlled Trial. J ECT 2017.</a></li><li><a class="nounderline abstract_t">Fitzgerald PB, Hoy KE, Elliot D, et al. Accelerated repetitive transcranial magnetic stimulation in the treatment of depression. Neuropsychopharmacology 2018; 43:1565.</a></li><li><a class="nounderline abstract_t">Fitzgerald PB, Hoy KE, Reynolds J, et al. A pragmatic randomized controlled trial exploring the relationship between pulse number and response to repetitive transcranial magnetic stimulation treatment in depression. Brain Stimul 2020; 13:145.</a></li><li><a class="nounderline abstract_t">Brunoni AR, Chaimani A, Moffa AH, et al. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. JAMA Psychiatry 2017; 74:143.</a></li><li><a class="nounderline abstract_t">Berlim MT, Van den Eynde F, Daskalakis ZJ. A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. Psychol Med 2013; 43:2245.</a></li><li><a class="nounderline abstract_t">Weissman CR, Blumberger DM, Brown PE, et al. Bilateral Repetitive Transcranial Magnetic Stimulation Decreases Suicidal Ideation in Depression. J Clin Psychiatry 2018; 79.</a></li><li><a class="nounderline abstract_t">Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY. Efficacy and acceptability of non-invasive brain stimulation for the treatment of adult unipolar and bipolar depression: A systematic review and meta-analysis of randomised sham-controlled trials. Neurosci Biobehav Rev 2018; 92:291.</a></li><li><a class="nounderline abstract_t">Mutz J, Vipulananthan V, Carter B, et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ 2019; 364:l1079.</a></li><li><a class="nounderline abstract_t">Chen JJ, Liu Z, Zhu D, et al. Bilateral vs. unilateral repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomized controlled trials. Psychiatry Res 2014; 219:51.</a></li></ol></div><div id="topicVersionRevision">Topic 113603 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074942" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067824" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Stuck in a rut: rethinking depression and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486154" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486154" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202547" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652560" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Repetitive transcranial magnetic stimulation is not as effective as electroconvulsive therapy for major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672044" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Whither TMS: A One-Trick Pony or the Beginning of a Neuroscientific Revolution?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31823735" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term deep-TMS does not negatively affect cognitive functions in stroke and spinal cord injury patients with central neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29373395" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Repetitive Deep TMS for Parkinson Disease: A 3-Month Double-Blind, Randomized Sham-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28156250" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy of deep rTMS for neuropathic pain in the lower limb: a randomized, double-blind crossover trial of an H-coil and figure-8 coil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30707989" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical review: The therapeutic use of theta-burst stimulation in mental disorders and tinnitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31892668" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intermittent theta burst stimulation applied during early rehabilitation after stroke: study protocol for a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504190" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Advancing Transcranial Magnetic Stimulation Methods for Complex Regional Pain Syndrome: An Open-Label Study of Paired Theta Burst and High-Frequency Stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28927961" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31230462" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Theta-Burst Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31109199" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038985" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29351885" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541649" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30098656" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder, Generalized Anxiety Disorder, and Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28747446" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439832" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215863" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Transcranial stimulation in depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27090022" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25034472" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474597" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29505184" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dr McClintock and Colleagues Reply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29505181" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Consensus Recommendations for rTMS in Depression: Not Entirely Correct!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833552" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29505183" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Roles and Qualifications of TMS Treatment Team Members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468992" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Update on magnetic seizure therapy: a novel form of convulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22037123" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A practical guide to the use of repetitive transcranial magnetic stimulation in the treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21485753" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22397890" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A double blind randomized trial of unilateral left and bilateral prefrontal cortex transcranial magnetic stimulation in treatment resistant major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25465290" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : rTMS of the dorsomedial prefrontal cortex for major depression: safety, tolerability, effectiveness, and outcome predictors for 10 Hz versus intermittent theta-burst stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19409383" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20539835" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : An efficient and accurate new method for locating the F3 position for prefrontal TMS applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32289680" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Reliability of targeting methods in TMS for depression: Beam F3 vs. 5.5 cm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20230934" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The value of neuronavigated rTMS for the treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32252538" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27551033" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Repetitive transcranial magnetic stimulation: an emerging treatment for medication-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294022" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21898711" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16911750" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Daily and spaced treatment with transcranial magnetic stimulation in major depression: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21910937" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22579164" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15652875" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621361" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of left prefrontal cortex in depression: a randomized sham controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633447" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bupropion decreases resting motor threshold: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23790811" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Maintenance transcranial magnetic stimulation reduces depression relapse: a propensity-adjusted analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683273" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An open label trial of clustered maintenance rTMS for patients with refractory depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844559" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A randomized, sham-controlled study of maintenance rTMS for treatment-resistant depression (TRD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401152" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term maintenance therapy for major depressive disorder with rTMS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17977787" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15792886" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31059991" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy of repetitive transcranial magnetic stimulation using a figure-8-coil or an H1-Coil in treatment of major depressive disorder; A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25655160" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29726344" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31477542" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A pilot investigation of an intensive theta burst stimulation protocol for patients with treatment resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32741289" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The Future Is Now? Rapid Advances by Brain Stimulation Innovation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28254709" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy of theta burst stimulation (TBS) for major depression: An exploratory meta-analysis of randomized and sham-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23190020" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Insights on the neural basis of motor plasticity induced by theta burst stimulation from TMS-EEG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976043" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Somatic treatments for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20734360" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29153439" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Number of pulses or number of sessions? An open-label study of trajectories of improvement for once-vs. twice-daily dorsomedial prefrontal rTMS in major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398915" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy of twice-daily vs once-daily sessions of repetitive transcranial magnetic stimulation in the treatment of major depressive disorder: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30527274" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Safety and Efficacy of Accelerated Repetitive Transcranial Magnetic Stimulation Protocol in Elderly Depressed Unipolar and Bipolar Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23896317" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25462419" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28072660" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Two Versus One High-Frequency Repetitive Transcranial Magnetic Stimulation Session per Day for Treatment-Resistant Depression: A Randomized Sham-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29467437" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Accelerated repetitive transcranial magnetic stimulation in the treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31521543" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A pragmatic randomized controlled trial exploring the relationship between pulse number and response to repetitive transcranial magnetic stimulation treatment in depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28030740" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23200131" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29701939" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bilateral Repetitive Transcranial Magnetic Stimulation Decreases Suicidal Ideation in Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29763711" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Efficacy and acceptability of non-invasive brain stimulation for the treatment of adult unipolar and bipolar depression: A systematic review and meta-analysis of randomised sham-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917990" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24889845" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Bilateral vs. unilateral repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
